Trial Profile

Phase I, Open Label Study to Evaluate Safety, Tolerability and Immunogenicity of Multiple Combinations of H1 and H5 Influenza Hemagglutinin Plasmids Administered ID Followed by in Vivo Electroporation With CELLECTRA-3P in Healthy Adults.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Apr 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FVH 1 (Primary) ; INO 3401 (Primary) ; INO 3510 (Primary) ; Influenza virus vaccine
Indications Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype
Focus Adverse reactions
Sponsors Inovio Pharmaceuticals

28 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
18 Apr 2013 Data for H1N1 were presented at the World Vaccine Congress, according to an Inovio Pharmaceuticals media release.
16 Mar 2012 Interim results are expected to be available in the second quarter of 2012.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com